Obsidian Therapeutics
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 1 year.
- Recent price momentum is -40.6% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has risen to 1.9% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Performance
Key statistics
Price & volume
- Prev close
- 12.15
- Open
- 12.01
- Day range
- 11.76 - 12.30
- Avg price
- 11.95
- Volume
- 336.50K
- Turnover
- 4.02M
- Turnover ratei
- 0.64%
- Volume ratioi
- 0.71
- Amplitudei
- 4.44%
- 52-week rangei
- 9.60 - 49.97
Valuation
- P/Ei
- 18.46
- P/E (TTM)i
- 18.46
- P/Bi
- 2.31
- EPSi
- 0.65
- Book value / shi
- 5.19
- Net profit
- 40.15M
- Net assets
- 320.61M
Share structure
- Market cap
- 741.29M
- Float capi
- 635.45M
- Shares out
- 61.77M
- Float sharesi
- 52.95M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- --
76.0% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-2.81M net over the window
Short interest
- Shares short
- 1.18M
- % of floati
- 1.92%
- Days to coveri
- 3.94
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Obsidian Therapeutics (OBX)?
Obsidian Therapeutics last traded at 12.00. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Obsidian Therapeutics's market cap?
About 741.29M.
What is the P/E ratio of Obsidian Therapeutics?
The trailing twelve-month P/E is 18.46, above its own 5-year average of 16.42 — in the middle of its historical range (33.78% percentile). See the Valuation tab for the full history.
Does Obsidian Therapeutics pay a dividend?
Obsidian Therapeutics does not currently pay a regular dividend.
Is Obsidian Therapeutics a buy according to analysts?
The consensus of 2 analysts is a Buy rating, with an average 12-month price target of 43.00, which implies 258.3% upside from the current price. This is not investment advice.
What is Obsidian Therapeutics's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Obsidian Therapeutics a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.
Obsidian Therapeutics discussion 0 comments